Diclofenac (Cataflam 50 mg) and Erlotinib: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
The erlotinib warning identifies a higher gastrointestinal-perforation risk with concomitant systemic NSAID use.
Clinical significance and safety
Erlotinib can rarely cause gastrointestinal perforation, and its label identifies concomitant systemic NSAID use as a factor that may increase the risk. Cataflam 50 mg contains diclofenac; the relevance depends on the regimen and individual gastrointestinal risk factors. This is a warning for coordinated review, not an automatic contraindication; severe abdominal pain needs urgent assessment.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.